Progressive Supranuclear Palsy - Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

As per Global Insight services' assessment, about 15+ prominent pharma and biotech giants are working on 15+ drugs in the Progressive Supranuclear Palsy - pipeline landscape globally. Progressive Supranuclear Palsy Pipeline Insight, 2023" report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.

Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:https://www.globalinsightservices.com/request-sample/GIS31301

Progressive Supranuclear Palsy is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech, and swallowing. Progressive supranuclear palsy typically begins in late middle age and worsens over time, with severe disability occurring within three to five years of onset. The disease can lead to serious complications such as pneumonia, choking, head injuries, and fractures.

Progressive supranuclear palsy is primarily caused by the accumulation of a protein called tau, as well as ageing and mitochondrial dysfunction, which is also a factor in progressive supranuclear palsy, particularly mitochondrial complex I inhibitors.

Report Highlights

Global Insight Service's, "Progressive Supranuclear Palsy - Drug Pipeline Landscape, 2023," an overview of the progressive supranuclear palsy pipeline drugs. This report covers detailed insights on progressive supranuclear palsy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to gain insights and thus help industry participants for decision making. Progressive supranuclear palsy pipeline report helps gaining insights on drugs which are under development stage of drug development process across globally. Global Insight Services aims to cover all the drug attributes, deals, regulatory milestones and all the upcoming milestones.

Recent Developments

In February 2023, Ferrer acquired worldwide rights from Asceneuron, which signed a licence agreement to develop and commercialise ASN90 on the PSP.

In June 2021, Pinteon extended collaboration with Lonza for manufacturing PNT001.

In July 2016, NeuroTau Inc received orphan drug designation from US FDA for Tolfenamic acid (NTX-010) for the treatment of progressive supranuclear palsy.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources carried out to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, clinical trials registries.

Scope

The pipeline landscape report consists of pipeline product based on several stages of development ranging from discovery to Pre-Registration. The report provides a review of pipeline therapeutics for progressive supranuclear palsy by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of progressive supranuclear palsy therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals and key upcoming milestones.

For In-Depth Competitive Analysis, Purchase this Report : https://www.globalinsightservices.com/checkout/single_user/GIS31301

Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -

- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.